Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ202 plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma
CTR20192600Phase 3Completed
- Sponsor
- Skyland Bio-Technology
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of felzartamab in multiple myeloma (MM), sponsored by Skyland Bio-Technology. Started Dec 2019; status: completed.
02
Drugs
felzartamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20192600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192600.